The DETECT Initiative in Early Alzheimer’s Disease: Optimizing Collaboration and Multidisciplinary Care to Facilitate Timely Diagnosis
Post-Test/Evaluation
Exit Survey
Questions marked with a
*
are required
28%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Alzheimer’s disease is the __________ leading cause of death in people 65 and older.
Third
Fourth
Fifth
Sixth
What percentage of people with AD are never diagnosed?
5%
10%
14%
20%
Which of the following is true when assessing Aβ42 levels?
Aβ42 levels decrease in cerebrospinal fluid (CSF)
Aβ42 plaques cannot be seen on amyloid PET scan
Aβ42 levels increase in CSF
Hypometabolism is a marker for abnormal Aβ42 levels
Who should manage patients with AD?
Primary care physicians
Neurologist
Neuropsychologist
Multidisciplinary team
A 56-year-old second-generation Korean woman who works as a psychologist is experiencing gradually increasing problems with judgment and memory over past 1-2 years, affecting her ability to do her job and her driving proficiency. Her husband is concerned for her health and welfare. This PET scan shows:
A pattern of hypometabolism that would rule out Lewy body disease
Bilateral frontal and temporal hypometabolism consistent with frontotemporal lobar degeneration
Bilateral temporal and parietal hypometabolism consistent with Alzheimer’s disease but possibly due to another disease
Bilateral temporal and parietal hypometabolism definitive for Alzheimer’s disease
A 63-year-old Caucasian-American man, retired police sergeant, referred by PCP. Gradually increasing “memory” difficulty over past 2 years. Often does not seem to remember common words, uses vague words when speaking, sometimes doesn’t seem to understand what others are saying to him (eg, “what is a steak?”). Has begun going for long walks most days and was recently found miles away from his house during a very cold day without a coat—near hypothermia. He is diagnosed with moderate AD. He should be offered all of the following EXCEPT:
A trial of aducanumab
Acetylcholinesterase inhibitors
Memantine
Clinical trial participation for disease modifying therapy (eg, donanemab) if he qualifies
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close